Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05813314 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
A Phase 1 study, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05813314: Clinical Trial Phase 1 study, sponsored by BioMarin Pharmaceutical.
NCT05813314 is a Phase 1 study that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05813314, a Phase 1 study, was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
Interventions
- COMBINATION_PRODUCT BMN 111 administration via Injector Pen
- DRUG BMN 111 administration via vial and syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 1 |
Why NCT05813314 stopped before completion
NCT05813314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which BMN 111 administration via Injector Pen is the first listed.
NCT05813314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05813314 about?
NCT05813314 is a clinical study titled "Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants". The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
What is the current status of trial NCT05813314?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-03-15. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT05813314?
The interventions under investigation include: BMN 111 administration via Injector Pen (COMBINATION_PRODUCT), BMN 111 administration via vial and syringe (DRUG).
Who is sponsoring clinical trial NCT05813314?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05813314's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI